Adam Keeney named head of corporate development at Biogen

US biotech major Biogen (Nasdaq: BIIB) has appointed Adam Keeney as executive vice president, head of corporate development effective April 17, 2023, adding a new face to its business development team.

Dr Keeney will be a member of Biogen’s executive committee reporting to Christopher Viehbacher, president and chief executive of the company, which has been under pressure since the controversial approval and dismal roll-out of the Alzheimer’s drug Aduhelm (aducanumab).

“We welcome Adam Keeney to our executive leadership team in this important role at this pivotal time for Biogen. Adam brings considerable experience in biopharmaceutical strategy and business development with a solid track record of value-creating deals throughout his career,” said Mr Viehbacher. “As we are working to put Biogen on a sustainable growth trajectory, Adam will focus on advancing the company’s strategy and pursuing external collaborations and other growth opportunities,” he noted.